Enjoy complimentary customisation on priority with our Enterprise License!
The lung cancer therapeutics market size is forecast to increase by USD 10.53 billion at a CAGR of 7.69% between 2023 and 2028. The market is experiencing significant growth, driven by the increasing adoption of precision medicine and research and development (RD) initiatives. The market is witnessing a heavy contribution from immunomodulators, a type of molecule, as part of the drug class, which is gaining popularity due to their targeted approach in treating lung cancer. Regenerative therapies, another emerging trend, are expected to revolutionize the treatment landscape, offering novel treatment options for patients. The therapy types, including targeted therapy, chemotherapy, and immunotherapy, continue to dominate the market. Astellas Pharma and other key players are investing heavily in RD to bring new drug classes and treatment types to the market.
The market is expected to grow steadily, offering significant opportunities for stakeholders.
Lung cancer is a leading cause of cancer-related deaths worldwide. The primary therapy types for lung cancer include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Unhealthy lifestyles, such as smoking, are significant risk factors for lung cancer. Early detection through medical diagnostic equipment and cancer awareness campaigns are essential for effective treatment. Targeted therapies, including precision medicine, have emerged as promising lung cancer therapeutics. These therapies focus on specific molecule types and drug classes to inhibit the growth of cancer cells. For instance, certain targeted therapies can inhibit the mutated genes found in non-small cell lung cancer. RD initiatives are ongoing to develop new therapies and improve existing ones.
Radiation therapy, chemotherapy, and surgery remain the mainstay of treatment for most lung cancer patients. Immunotherapy, a relatively new therapy type, has shown promising results in treating advanced lung cancer. Lung carcinoid tumor, a rare type of lung cancer, requires specific treatment approaches. In conclusion, the lung cancer therapeutic market is evolving, with a focus on targeted therapies and precision medicine. The development of new therapies and improved diagnostics will continue to shape the market landscape.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The targeted therapy segment is estimated to witness significant growth during the forecast period.Lung cancer, a disease with a high incidence rate, is primarily caused by smoking and second-hand smoke exposure. The therapeutics market for this disease is witnessing significant growth due to the approval of new targeted therapies. The targeted therapy segment of the market comprises drugs that inhibit tumor blood vessel growth, such as CYRAMZA, and those that target cells with specific gene mutations, including Tarceva, Gilotrif, IRESSA, TAGRISSO, VIZIMPRO, XALKORI, ZYKADIA, ALECENSA, ALUNBRIG, LORBRENA, TAFINLAR, and MEKINIST. These drugs specifically target mutations in the EGFR, T790M, ALK, and BRAF genes. The segment's growth can be attributed to the increasing prevalence of chronic diseases like lung cancer and the recent approval of these new targeted therapies, such as Avastin, Taxotere, and Gemzar.
The market is expected to continue its accelerated growth during the forecast period.
Get a glance at the market share of various segments Request Free Sample
The Targeted therapy segment accounted for USD 9.39 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Lung cancer is a major health concern, with smoking and second-hand smoke being the primary risk factors. According to the American Cancer Society, lung cancer has the highest incidence rate and is the leading cause of cancer deaths worldwide. In North America, the market for lung cancer therapeutics holds the largest revenue share, driven by the high prevalence of lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), in the region. The National Institutes of Health (NIH) reports that while the incidence rate of lung cancer in the US has decreased, the overall prevalence of the disease has increased significantly.
Key therapeutics for lung cancer include Avastin, Tarceva, Taxotere, and Gemzar. The high incidence rate and mortality of lung cancer are expected to fuel market growth in North America during the forecast period.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The heavy contribution of immunomodulators is the key driver of the market. The global market for lung cancer therapeutics has experienced a notable expansion in recent times, driven mainly by the approval of immunomodulators, specifically PD-1 and PD-L1 inhibitors. Four such drugs, KEYTRUDA, IMFINZI, TECENTRIQ, and OPDIVO, have been authorized for the treatment of NSCLC and are currently under investigation for SCLC indications. These immunotherapies have shown superior progression-free survival (PFS), overall survival rate (OSR), and objective response rate (ORR) in NSCLC patients and other cancer types compared to conventional chemotherapy. Unhealthy lifestyles and tobacco use continue to fuel the incidence of lung cancer, ensuring a consistent demand for effective therapeutic solutions.
The advent of regenerative therapies is the upcoming trend in the market. The global market for lung cancer therapeutics is witnessing significant advancements in response to the growing prevalence of this malignancy, particularly Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). Current treatment modalities include chemotherapy, surgery, and radiation therapy. While chemotherapy, immunomodulators, and other biological drugs are effective in managing NSCLC and SCLC, they do not guarantee a cure. To address this challenge, research and development efforts are underway to introduce regenerative therapies, such as gene therapies, to the market. Targeted therapies, which focus on specific genetic abnormalities underlying NSCLC, represent a promising avenue for treatment. These therapies, including immunomodulators, can enhance treatment efficacy and potentially improve patient outcomes.
However, the development of these advanced therapeutic options requires substantial investment and time. As the burden of lung cancer continues to rise due to unhealthy lifestyles and tobacco use, the need for innovative therapeutic solutions is increasingly urgent. companies are collaborating with academic institutions and research organizations to accelerate the discovery and development of novel lung cancer therapies. This collaborative approach is expected to yield significant advancements in the field and ultimately benefit patients.
Adherence to available alternatives is a key challenge affecting the market growth. Lung cancer is a major health concern, with unhealthy lifestyles, particularly tobacco use, being the leading causes. In the early stages of Non-Small Cell Lung Cancer (NSCLC), surgery and radiation therapy are the most common treatment modalities. The long-term use of therapeutics, such as chemotherapy, targeted therapy, and immunotherapy, can be costly and time-consuming. Moreover, NSCLC often remains localized during the early stages, making surgical intervention highly effective. Video-assisted thoracoscopic surgery (VATS) is a minimally invasive surgical procedure used for treating early-stage NSCLC. Radiation therapy, in combination with chemotherapy, is also an effective treatment option for patients who are not candidates for surgery.
Targeted therapy and immunotherapy are emerging treatment modalities that offer promising results, especially for advanced-stage NSCLC. However, their high costs and potential side effects limit their widespread use.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers lung cancer therapeutics namely Teliso-V.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Lung cancer is a leading cause of cancer-related deaths worldwide, with the American Cancer Society estimating over 130,000 new cases and 60,000 deaths in the US alone in 2021. Unhealthy lifestyles, tobacco use, second-hand smoke, and rising pollution levels are significant risk factors. Current therapeutic approaches for lung cancer include radiation therapy, chemotherapy, surgery, targeted therapy, and immunotherapy. Targeted therapies, such as Avastin, Tarceva, Taxotere, and Gemzar, which target specific molecules or gene mutations, have shown promising results. Advanced therapeutics, like nanomedicine, are under investigation for improved efficacy and reduced side effects. Cancer awareness campaigns and medical diagnostic equipment play a crucial role in early detection.
Stringent regulations ensure the safety and efficacy of lung cancer therapeutics. Adorx Therapeutics is developing new therapies using biomarkers to personalize treatment for patients with epithelial cell lung cancer. RD initiatives focus on precision medicine and therapy type classification based on drug class and treatment type.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
171 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.69% |
|
Market Growth 2024-2028 |
USD 10.53 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.99 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 46% |
|
Key countries |
US, UK, Canada, China, and France |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galecto Inc., GlaxoSmithKline Plc, IOVANCE Biotherapeutics Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Moderna Inc., Novartis AG, Parexel International Corp., Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
